Peer-reviewed veterinary case report
Masitinib treatment for metastatic and non-resectable dog skin tumors
By Smrkovski, O A et al.·Published in Veterinary and comparative oncology·2015·Department of Small Animal Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
- Species:
- dog
Plain-English summary
A group of 26 dogs with skin tumors called mast cell tumors (MCTs) were treated with a medication called masitinib mesylate. About half of the dogs responded well to the treatment, with those that did living an average of 630 days compared to just 137 days for those that didn’t respond. While some dogs experienced mild side effects, most were manageable. The study found that how well the dogs responded to masitinib was more important for their survival than the tumor's grade or location.
People also search for: dog mast cell tumor treatment · masitinib for canine cancer · mast cell tumor survival rate in dogs
Abstract
Masitinib mesylate is a tyrosine kinase inhibitor approved for the treatment of gross, non-metastatic grade II and III canine mast cell tumours (MCTs). This study evaluated the use of masitinib as a frontline and rescue agent for metastatic and non-metastatic canine MCTs. Identification of toxicities and prognostic factors in these dogs was of secondary interest. Twenty-six dogs were included in this study. The overall response rate to masitinib was 50%. The median survival time for dogs that responded to masitinib was 630 days versus 137 days for dogs that did not respond (P = 0.0033). Toxicity was recorded in 61.5% of treated dogs, but the majority of adverse events were mild and self-limiting. Response to masitinib, not tumour grade, stage or location, was the most significant prognostic factor for survival in dogs with MCTs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23845124/